尽管已经针对非小细胞肺癌(NSCLC)开发了许多策略,由于耐药性或肿瘤复发,需要更多的二次和进一步的治疗。阿帕替尼是一种新型的口服抗血管生成药,在本研究中,我们的目的是探讨阿帕替尼在严重预处理的NSCLC中的临床价值.这里,我们报告了特征,阿帕替尼(500mg/d)治疗的3例患者的疗效和不良事件。我们还总结了目前可用的证据和正在进行的关于阿帕替尼在NSCLC中使用的临床试验。2例腺癌和1例鳞状细胞癌患者因既往化疗和表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗后病情进展而接受阿帕替尼治疗。所有患者对阿帕替尼反应迅速,此后不久发生耐药性。鳞状细胞癌患者因咯血死亡。其他不良事件均可接受。比较了所有以前的相关研究,并显示出相似的结果,但无进展生存期更长。此外,系统检索并列出正在进行的临床试验.总之,阿帕替尼在重度治疗的NSCLC中显示出一定的疗效,在非鳞状NSCLC中显示出一般可耐受的毒性.在不久的将来将获得更多确凿的证据。
Although many strategies have been developed for non-small cell lung cancer (NSCLC), more secondary and further treatments are needed due to drug resistance or tumor recurrence. Apatinib is a novel oral antiangiogenic agent and in this study, we aim to investigate the clinical value of apatinib in heavily pretreated NSCLC. Here, we reported the characteristics, efficacy and adverse events of three patients treated with apatinib (500 mg/day). We also summarized the currently available evidence and ongoing clinical trials regarding the use of apatinib in NSCLC. Two cases of adenocarcinoma and one
case of squamous cell carcinoma were treated with apatinib due to disease progression after previous treatments of chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). All patients responded to apatinib rapidly and underwent drug resistance shortly afterwards. The patient with squamous cell carcinoma died of hemoptysis. Other adverse events were acceptable. All previous relevant studies were compared and showed similar results but a longer progression-free survival. Additionally, ongoing clinical trials were systematically searched and listed. In conclusion, apatinib shows some efficacy in heavily treated NSCLC and generally tolerable toxicity in non-squamous NSCLC. More solid evidence will be accessible in near future.